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Response to treatment 
Inflammatory biomarkers 
A B S T R A C T   
Purpose: The aim of this study was to explore the utility of inflammatory biomarkers in the peripheral blood to 
predict response to treatment in extrapulmonary tuberculosis (EPTB). 
Methods: A Luminex xMAP-based multiplex immunoassay was used to measure 40 inflammatory biomarkers in 
un-stimulated plasma of 91 EPTB patients (48 lymphadenitis, and 43 pleuritis) before and at 2 and 6 months of 
treatment. 
Results: Overall a significant change was observed in 28 inflammatory biomarkers with treatment in EPTB pa-
tients. However, MIG/CXCL9, IP-10/CXCL10, and CCL23 decreased in all patients’ groups with successful 
treatment at both time points. At 2 months, 29/64 (45%) patients responded partially while 35/64 (55%) 
showed complete regress. Among good responders, a higher number of biomarkers (16/40) reduced significantly 
as compared to partial responders (1/40). Almost half (14/29) of partial responders required longer treatment 
than 6 months to achieve satisfactory response. The levels of MIG, IP-10, MIF, CCL22 and CCL23 reduced 
significantly among 80, 74, 60, 71, 51% good responders, as compared to 52, 52, 52, 59, 52% partial responders, 
respectively. A biosignature, defined by a significant decrease in any one of these five biomarkers, corresponded 
with satisfactory response to treatment in 97% patients at 2 month and 99% patients at 6 months of treatment. 
Conclusion: Change in inflammatory biomarkers correlates with treatment success. A five biomarker biosignature 
(MIG, IP-10, MIF, CCL22 and CCL23) could be used as an indicator of treatment success.   
1. Introduction 
Tuberculosis (TB) continues to be a major cause of morbidity and 
mortality in low and middle-income countries [1]. The global burden of 
the disease is estimated to be around 10 million as per World Health 
Organization and the prevalence of extrapulmonary TB (EPTB) is up to 
24% of all notified TB cases [2]. The diagnosis of EPTB is challenging 
due to high variability in clinical presentation and difficulty in obtaining 
a representative sample from the disease site for microbiological 
confirmation. Moreover, due to the paucibacillary nature of the disease, 
sensitivity of the routine microbiological tests is low [3,4]. This often 
leads physicians to diagnose EPTB on clinical basis followed by 
administration of anti-TB treatment without bacteriological confirma-
tion [5]. Monitoring response early during treatment is, therefore, 
critical to reduce overtreatment, development of drug resistance, 
morbidity, and mortality. For patients that have bacteriologically 
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confirmed EPTB, monitoring response during treatment is equally 
important as the treatment involves a prolonged administration of 
multiple antimicrobials and the decision on duration of treatment often 
depends on the patients’ response to prevent relapse. In case of smear- 
positive pulmonary TB, smear conversion is an important criterion for 
assessing response to treatment [6]. However, in case of EPTB, it is 
difficult to obtain repeated samples from the disease site during treat-
ment, and response to treatment often relies on clinical criteria [7]. 
Currently, there is a lack of reliable objective criteria that can be used in 
the routine clinical practice for monitoring response to treatment in 
EPTB [7,8]. Some studies have explored the change in the levels of 
different immune biomarkers for this purpose [9,10]. However, most of 
the studies have small sample sizes [11,12], or use stimulation of im-
mune cells [13–15]. Measurement of biomarkers in un-stimulated pa-
tient’s plasma provides a direct means to observe the changes in 
biomarkers in response to treatment [16]. The aim of this study was to 
investigate change in the levels of inflammatory biomarkers in the un- 
stimulated plasma of EPTB patients during the treatment and their 
utility to accurately predict the response to treatment. 
2. Material and methods 
The study was conducted at Gulab Devi Hospital, a private not-for- 
profit tertiary care hospital located in Lahore, Pakistan, and provides 
specialized TB care. Presumptive and diagnosed TB patients are referred 
from various districts for consultation and/or treatment at Gulab Devi 
Hospital Lahore. Patients of all ages with presumptive EPTB attending 
outpatient clinics were enrolled from April 2016 to August 2017. All 
patients received standard anti-TB treatment and followed up till the 
satisfactory response to treatment. Blood samples (5 ml) were collected 
at before initiation of anti-TB treatment (baseline) and at 2 and 6 months 
after treatment, centrifuged for 10 min at 1000g, plasma collected and 
frozen at − 20 ◦C for a few months and then shifted to − 80 ◦C until use. 
2.1. Laboratory methods 
For patients with enlarged lymph nodes, an excision biopsy was 
performed, and the sample was sent for histopathology and microbio-
logical examination. For patients with pleural effusions, aspirated fluid 
was sent for cytology and microbiological workup. The specimens were 
processed for smear examination, Xpert MTB/RIF assay (Xpert), and 
culture [17]. Auramine O-stained smears were examined using a light- 
emitting diode fluorescence microscope [18]. Xpert was performed ac-
cording to manufacturer’s protocols [19]. Two slopes of Lowenstein- 
Jensen medium and one Mycobacteria Growth Indicator Tube 
(MGITTM 960TM; Becton Dickinson, Sparks, MD, USA) were inoculated 
for culture [17]. 
2.2. Inflammatory biomarkers detection through multiplex microbead 
immunoassay 
Biorad 40 plex Bio-PlexProTMHuman Chemokine Panel (Table 1), 
was used on Luminex® xMAP™ to detect cytokines/chemokines from 
the plasma (Referred to as inflammatory biomarkers in the text). Frozen 
plasma samples were thawed, mixed by vortexing, and centrifuged for 
10 min at 10,000g to remove particulates before the assays were per-
formed. Plasma samples were analyzed in duplicates in the first exper-
iment and singlets in the succeeding experiments as inter-assay 
variability was in the acceptable range. Blanks and standards were run 
in duplicates in all experiments. Assays were performed as per manu-
facturer’s instructions (BioRad, Hercules, CA). Briefly, after pre-wetting 
the plates, 50 μl of 1x beads were added to wells, plates were washed 
twice and 50 ul of standards, controls, and samples were added to the 
respective wells. After one hour’s incubation on a shaker at room tem-
perature, plates were washed 3 times and 25 ul of detection antibodies 
were added to each well. After an incubation of 30 min at room tem-
perature and washing thrice, 50 ul of streptavidin-E was added to each 
well. Plates were incubated for another 10 min on the shaker at room 
temperature and after three steps of washings, re-suspended with 125 ul 
of assay buffer. Plates were read with a Luminex instrument (Luminex 
200, Austin Luminex, USA). Data was analyzed using MILLIPLEX Ana-
lyst 5.1 software (Merck Millipore Darmstadt, Germany), as per the 
manufacturer’s instructions. 
2.3. Case definition 
Using a combination of clinical, radiological, and laboratory find-
ings, cases were defined as confirmed and probable EPTB cases. A 
confirmed case was defined based on the bacteriological confirmation 
either on culture or Xpert. A probable TB pleuritis case was defined if the 
symptoms and findings were consistent with TB pleuritis (lymphocytosis 
and fluid protein level more than 3 g/dl or plasma adenosine deaminase 
levels more than 16 U/L or concomitant pulmonary TB suggested by 
positive acid-fast bacilli smear and/or chest radiograph) and with good 
response to anti-TB treatment at 2–3 months and/or end of treatment. A 
probable TB lymphadenitis case was defined if the symptoms, clinical 
findings, and histopathology were consistent with TB lymphadenitis and 
with good response to anti-TB treatment at 2–3 months and /or end of 
the treatment. 
2.4. Response to treatment 
The response to treatment was considered as good if two of these 
three criteria were fulfilled, 1) regression of symptoms, 2) regression of 
local signs of disease; regression of lymph nodes among lymphadenitis 
cases and regression of pleural effusion assessed by ultrasound among 
the pleuritis cases, 3) weight gain. 
2.5. Statistical analysis 
International Business Machine (IBM) – Statistical Package for Social 
Sciences (SPSS) version 23 and R studio were used for data analysis. 
Data were evaluated for normality using Shapiro-Wilk and Kolmogorov- 
Smirnov tests. For normally distributed data, paired t-test was used, 
otherwise non-parametric Wilcoxon signed rank test was employed for 
analysis of data. Chi-square test was done for categorical data. A p-value 
< 0.05 was considered statistically significant. Furthermore, Linear 
Discriminant Analysis was used to classify cytokines at baseline and at 
two points after treatment. Ratio (or pirate) plots with 95% highest 
density interval were used to visualize the ratio of change in the 
biomarker levels for individual patients. 
Different biosignatures were synthesized by making a combination of 
the inflammatory biomarkers which showed statistically significant 
change in the median levels at two timepoints during treatment as 
Table 1 
Cytokine and chemokine panel used on plasma samples of the TB pleuritis and 
lymphadenitis patients.  
Pro-inflammatory 
cytokines 
Interferon-gamma (IFN-γ), Tumor necrosis factor Alpha 




Chemokines CCL 6Ckine/CCL21, CTACK/CCL27, Eotaxin/CCL11, 
Eotaxin-2/CCL24, Eotaxin-3/CCL26, 309/CCL1, 
MCP-1/CCL2, MCP-2/CCL8, MCP-3/CCL7, MCP- 
4/CCL13, MDC/CCL22, TECK/CCL25, TARC/ 
CCL1, MIP-3β/CCL19, MIP-3α /CCL20, MPIF-1/ 
CCL23, MIP-1δ/CCL15  
CXCL BCA-1/CXCL13, ENA-78/CXCL5, GCP-2/CXCL6, 
Gro-α/CXCL1, Gro-β/CXCL2, IL-8/CXCL8, IP-10/ 
CXCL10, I-TAC/CXCL11, MIG/CXCL9, SDF- 
1α+β/CXCL12, SCYB16/CXCL16  
CX3CL Fractalkine/CX3CL1 
Growth factors Granulocyte-macrophage colony-stimulating factor (GM- 
CSF), IL-2  
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compared to the baseline, and each biomarker showed ≥20% change 
from the baseline in an individual patient. A software library, Python 
And Data Analysis (Pandas), was used for basic data manipulation and 
all the possible combinations of members of the given biomarkers set 
were computed. The biomarker combinations covering the greatest 
number of patients and the least number of biomarkers were selected. 
3. Results 
3.1. Patients characteristics 
Fig. 1 shows the patients included in the study. A total of 671 pre-
sumptive EPTB cases were investigated during the study period. Among 
them, 364 were registered at Gulab Devi Hospital. A total of 91 patients 
were included in the study. The demographic and clinical characteristics 
of study participants are shown in Table 2. There were 48 TB lymph-
adenitis and 43 TB pleuritis cases. Using a composite reference standard, 
51 patients were classified as confirmed, and 40 as probable EPTB cases. 
The median age was 20 years for lymphadenitis and 25 years for 
pleuritis patients. There was a preponderance of females (75%) among 
lymphadenitis patients while the majority (70%) of patients presenting 
with pleuritis were males. None of these patients was positive for human 
immunodeficiency virus. One lymphadenitis and 3 pleuritis patients had 
a history of having diabetes. All other patients had random blood sugar 
levels less than 200 mg/dl. At the second month of treatment 20/48 
(42%) lymphadenitis and 32/43 (74%) pleuritis patients showed satis-
factory response to treatment with improvement of clinical and sub-
jective criteria. Rest of the patients showed clinical improvement but not 
complete resolution of signs and symptoms. At 6 months of treatment, 
44/48 lymphadenitis and 41/43 pleuritis patients turned up for follow- 
up. Treatment was extended for 20 patients (15 lymphadenitis and 5 
pleuritis), 16 of these 20 patients showed partial response at 2 months of 
treatment. Clinical improvement was recorded in all patients at the end 
of the treatment. 
3.2. Inflammatory biomarker profile change with treatment in TB 
lymphadenitis 
Fig. 2 shows the 16 biomarkers that changed significantly with 
treatment as compared to the baseline. After 2 months of treatment, 
there was a significant decrease in the plasma levels of MIG (p = .007), 
IP-10 (p = .025), CXCL2 (p = .042), CCL8 (p = .048), CCL22 (p = .003), 
and CCL23 (p = .009), and an increase in the plasma levels of TNF-α (p =
EPTB cases registered for 
treatment = 364
TB lymphadenitis = 48
Bacteriology confirmed cases = 38 
Probable EPTB cases = 10
TB pleuritis = 43
Included in the study = 94
Not included in the study = 270
(Sample either not collected at 0 
M or if present at 0 M missing at 
both 2 and 6 M)
Bacteriology confirmed cases = 13
Probable EPTB cases = 30
Patients with sample at
0 M + 2 M + 6 M =30
0 M + 2 M = 8
0 M + 6 M = 10
Patients with sample at
0 M + 2 M + 6 M = 18
0 M + 2 M = 8
0 M + 6 M = 17
Non-Tuberculous Mycobacteria 
(Mycobacterium Fortuitum) = 3 Multiplex analysis performed = 91
Presumptive EPTB cases investigated  
(April 2016- August 2017) = 671
Fig. 1. Flow chart showing patients included in the study and the number of plasma samples obtained at different time points during treatment. Abbreviations, TB: 
tuberculosis, EPTB: extrapulmonary tuberculosis, M: Month of the treatment. 
Table 2 
Demographic and clinical characteristics of extrapulmonary tuberculosis 
patients.  
Patient Characteristics TB lymphadenitis N 
= 48 
TB pleuritis N 
= 43 
Age in years, median, (range) 20 (11–72) 25 (15–70) 
Sex, n (%)   
Male 12 (25) 30 (70) 
Female 36 (75) 13 (30) 
HIV status, n (%)   
Positive 0 (0) 0 (0) 
Negative 48 (100) 43 (100) 
History of Diabetes, n/N (%)   
Yes 1/45 (2) 3/37 (8) 
No 44/45 (98) 34/37 (92) 
NA 3/48 (6) 6/43 (14) 
Patient Categorization, n/N (%)   
Confirmed TB 38/48 (79) 13/43 (30) 
Culture positive 11/38 (29) 10/13 (77) 
Xpert Positive 3/38 (8) 1/13 (8) 
Both positive 24/38 (63) 2/13 (15) 
Probable TB 10/48 (21) 30/43 (70) 
Clinical response at 2 M of treatment, 







Clinical response at 6 M/end* of 
treatment, n/N (%)   
Responders 44/44 (100) 41/41 (100) 
N: Total number, n: number, %: percentage, NA : no information available TB: 
tuberculosis, M: month. 
* Treatment was extended for 15 lymphadenitis and 5 pleuritis patients 
beyond 6 months. 
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Fig. 2. Box plots showing plasma levels of inflammatory biomarkers in lymphadenitis patients at baseline, 2, and 6 months of treatment. Biomarkers that changed 
significantly with treatment are shown. The Wilcoxon signed rank test was used to compare biomarkers expression at different time points. A p-value < 0.05 was 
considered significant. Boxes represent the median and interquartile range, and the whisker represents minimum/maximum values. Outliers are shown by a broken 
axis. n = number of patients. 
Fig. 3. Linear discriminant analysis (LDA) at baseline and at 2 & 6 months of treatment. a: LDA for tuberculous lymphadenitis patients (n = 30). LDA gave significant 
classification (Wilk Lambda = 0.016) with a membership of 100% at 6 months. b: LDA for tuberculous pleuritis patients (n = 18). Although statistical significance 
was not obtained (Wilk Lambda = 0.119, with a membership of 62.5% at 6 months) due to small sample size, there is a visible trend of separate clustering at 0, 2, and 
6 months. 
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.021), CCL2 (p = .004), CCL3 (p = .005), CCL13 (p = .045) and CCL26 (p 
= .008). After 6 months of treatment, levels of MIG (p < .001), IP-10 (p 
= .024), MIF (p = .044), IL-1β (p = .004), CXCL11 (p = .004), and CCL23 
(p = .003) decreased significantly, while levels of CCL2 (p = .013), 
CCL13 (p = .002), CCL26 (p = .028), CXCL1 (p = .007), and CXCL12 (p 
= .022) increased significantly as compared to the baseline. 
Linear discriminant analysis (Fig. 3a) gave a significant classification 
of patients with respect to their above-mentioned inflammatory bio-
markers’ levels at baseline, 2, and 6 months, further depicting signifi-
cant change in the levels of inflammatory biomarkers after treatment at 
both time points, with a membership of 100% at 6 months. 
Fig. 4 shows the ratio of change in the levels of above-mentioned 
biomarkers in individual patients at both time points showing wide 
variation between individual patients. All the above-mentioned bio-
markers did not change in all patients. Table 3 shows the proportions of 
patients in which the individual biomarkers showed ≥20% change from 
the baseline in an individual patient. The magnitude of change (fold 
change) also varied between biomarkers ranging from 2- to12-fold 
change (Table 3). 
3.3. Inflammatory biomarker profile change with treatment in TB pleuritis 
Fig. 5 shows the 24 inflammatory biomarkers that changed signifi-
cantly with treatment as compared to the baseline. After two months of 
treatment, a significant decrease in plasma levels of MIG (p = .002), IP- 
10 (p < .001), IFN-γ (p = .004), IL-4 (p = .022), CCL1 (p < .001), CCL8 (p 
Fig. 4. Ratio/pirate plots to visualize the 
decrease or increase in plasma levels of in-
flammatory biomarkers in the individual 
tuberculous (TB) lymphadenitis patients. 
Only those inflammatory biomarkers that 
changed significantly with treatment are 
shown. a: Ratio of plasma level of inflam-
matory biomarkers at 2 month of treatment 
to their levels at baseline (n = 38) *Outliers: 
CCL13: 7 & 159, CCL2: 6; 14; 16 & 27, 
CCL22: 20, CCL23: 14, CCL3: 6; 8; 14; 22; 22; 
26; 27; 76 & 209, CCL8: 1300, CXCL2: 8; 10 
& 139, CCL26: 7; 8; 8; 10; 12; 22; 25; 164; 
241 & 351, IP10: 6 & 8, TNF-α: 6; 9; 9 & 40. 
b: Ratio of plasma levels of inflammatory 
biomarkers at 6 months of treatment to their 
levels at the start of treatment (n = 40) 
*Outliers: CCL13: 6; 7; 7; 9 & 9, CCL2: 8 & 
166, CCL23: 7 &15, CCL26: 6, 8, 9, 9, 10, 14, 
42, 76, 104, 164 & 176, CXCL1: 6, 6, 8, 9, 12, 
15, 17 & 551, CXCL12: 6, 6, 7, 8, 8, 26 & 
251, IP10: 6, MIF: 10, 18, 31, 80 & 116.   
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< .001), CCL20 (p = .005), CCL22 (p = .002), CCL23 (p = .001), CCL24 
(p = .012), CXCL2 (p < .001), CXCL11 (p = .001), and CX3CL1 (p =
.016), and an increase in levels of IL-8 (p = .012), CCL26 (p = .028), and 
CCL13 (p = .034) was observed. After 6 months of treatment, a signif-
icant decrease was seen in the levels of 18 inflammatory biomarkers as 
compared to the baseline. These included MIG (p < .001), IP-10 (p <
.001), IFN-γ (p = .002), MIF (p = .013), IL-4 (p = .035), IL-6 (p < .001), 
CCL1 (p < .001), CCL3 (p = .038), CCL8 (p = .003), CCL15 (p = .041), 
CCL17 (p = .013), CCL19 (p = .036), CCL20 (p = .011), CCL23 (p <
.001), CXCL2 (p = .027), CXCL6 (p = .021), CXCL11 (p < .001), and 
CX3CL1 (p = .023). However, a significant increase was seen for only 
CCL2 (p = .012). 
Linear discriminant analysis as shown in Fig. 3b gave a significant 
classification of patients with respect to their above-mentioned inflam-
matory biomarkers’ levels at 2 months but not at 6 months. However, at 
6 months, there was a visible trend depicted by clustering when 
compared with the baseline. 
Fig. 6 shows the ratio of change in the levels of above-mentioned 
biomarkers in individual patients at both time points. As in lymphade-
nitis, a wide variation was seen between individual patients. All the 
above-mentioned biomarkers did not change in all patients. Table 3 
shows the proportions of patients in which the individual biomarkers 
showed ≥20% change from the baseline in an individual patient. The 
magnitude of change (fold change) also varied between biomarkers 
ranging from 2- to12-fold change (Table 3). A biomarker with higher 
fold change implies its robustness as an indicator of treatment response. 
3.4. Common inflammatory biomarkers changing in both TB pleuritis and 
lymphadenitis 
Fig. 7 shows the common biomarkers that changed significantly in 
both patient groups at both time points. After two months of treatment, 
MIG, IP-10, CXCL2, CCL8, CCL22, and CCL23 decreased, while CCL13, 
and CCL26 levels increased in both groups. At 6 months, levels of MIG, 
MIF, IP-10, CCL23, and CXCL11 decreased and the level of one 
biomarker (CCL2) increased in both groups of patients. 
Table 3 
Proportion of tuberculous lymphadenitis and pleuritis patients showing ≥20% 
change in the levels of biomarkers in response to treatment and the magnitude of 
change (fold change) in median plasma levels.  
Biomarkers TB lymphadenitis TB pleuritis 
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(69) 
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CXCL12   26/ 
40 
(65) 
3↑     
CXCL1   25/ 
39* 
(64) 
4↑     
MIF   27/ 
40 
(68) 




IL-1β   27/ 
40 
(68) 
3↓     














CCL24     19/ 
26 
(73) 
12↓   
IL-8     12↑    
Table 3 (continued ) 
Biomarkers TB lymphadenitis TB pleuritis 








































FC: fold change, n: number of patients showing significant change, N: total 
number of patients, ↓: decrease, ↑: increase. 
ф From baseline to 2 months after treatment. 
¥ From baseline to 6 months after treatment. 
* Valid available values. 
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3.5. Biosignature predicting response to treatment in all patients 
Biosignatures were synthesized by different possible combinations of 
biomarkers on the condition that change in any one of the biomarkers in 
the biosignature would predict response to treatment. The goal was to 
have a biosignature with minimum number of biomarkers changing in 
maximum number of patients and in both forms of TB. When all 
significantly changed biomarkers were used, the number of possible 
combinations became too high. We, therefore, selected five biomarkers, 
MIG, IP-10, MIF, CCL22, CCL23, based on their high baseline levels, and 
their change in higher proportion of patients. All possible combinations 
with these five biomarkers are shown in (Online Resource 1) Supple-
mentary Tables 1, 2, & 3. Table 4 shows the selected biosignatures and 
their sensitivity to predict response to treatment at 2 and 6 months of the 
treatment. A biosignature (MIG + IP-10 + MIF + CCL22 + CCL23), 
could predict response to treatment in 97% patients at 2 months and 
99% patients at 6 months of treatment. 
3.6. Change in plasma inflammatory biomarkers correlates with early 
clinical response during treatment 
After 2 months of treatment, 35/64 (55%) patients (16 lymphade-
nitis and 19 pleuritis) showed good clinical response (responders), while 
29/64 (45%) patients (22 lymphadenitis and 7 pleuritis) improved 
clinically but clinical signs did not settle completely (partial re-
sponders). Fig. 8 shows the levels of biomarkers among responders and 
partial responders. A total of 16 inflammatory biomarkers decreased 
significantly in responders while only one decreased in partial re-
sponders, indicating that a decrease in plasma levels of these biomarkers 
at 2 months correlates with good clinical response. Furthermore, re-
sponders showed significant decline in four of the biomarkers (MIG, IP- 
10, CCL22, CCL23) included in the biosignature as compared to the 
partial responders who showed significant change in only one (CCL23). 
Extension of treatment was required for 20 patients and 16/20 were 
partial responders. Plasma samples were available for 14/16 patients at 
2 months. This implies that these biomarkers can also be used to predict 
which patients would require prolonged treatment beyond 6 months. 
Although decrease in MIF levels did not reach statistical significance at 
2 months, ≥ 20% decrease was seen in 60% responders and 52% partial 
responders (Fig. 8). 
4. Discussion 
In this prospective cohort study, we have shown that plasma levels of 
several inflammatory biomarkers change with treatment. The patients’ 
response to infection and treatment would depend on a variety of host 
and bacteriological factors and is expected to vary among individuals 
and between different disease sites. A single inflammatory biomarker is, 
therefore, not expected to give a satisfactory response in all patient 
categories, while a combination of biomarkers can predict response to 
treatment with reasonable certainty in many patients as shown in our 
study. Individually, the levels of IP-10, MIG, and CCL23 changed 
significantly in majority of TB lymphadenitis and TB pleuritis patients at 
both 2 and 6 months after treatment. A combination of five inflamma-
tory biomarkers (MIG, IP-10, MIF, CCL22 and CCL23) could predict 
response to treatment in 97% of our study patients at 2 and 99% at 6 
months after treatment. 
Several studies have shown that MIG, MIF, IP-10 and CCL22 plasma 
levels increase in active TB and decline with successful treatment and 
have been proposed as surrogate markers for the evaluation of treatment 
response in pulmonary and EPTB. However, the main focus of these 
studies has been pulmonary TB with relatively few EPTB cases [20–24]. 
Few other studies have shown various combinations of biomarkers in 
plasma [9] or saliva [25] to assess response to treatment in pulmonary 
TB. To our knowledge this is the first study to evaluate the role of 40 
inflammatory biomarkers in >90 EPTB patients at two time points after 
treatment. 
Although several biomarkers changed with treatment, and many 
Fig. 5. Box plots showing changes in plasma levels of inflammatory biomarkers in tuberculous pleuritis patients at baseline and 2, and 6 months of treatment. 
Biomarkers that changed significantly with treatment are shown. The Wilcoxon signed rank test was used to compare biomarkers expression at different time points. 
A p-value < 0.05 was considered significant. Boxes represent the median and interquartile range, and the whisker shows minimum/maximum values. Outliers are 
shown by a broken axis. n = number of patients. 
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combinations gave good sensitivity in assessing response to treatment, 
we selected a biosignature comprising of the biomarkers with, i) a 
persistent trend (downward or upward) throughout the treatment, ii) 
high plasma levels, iii) high fold change and iv) giving coverage to 
maximum number of patients. The relatively high plasma levels make 
them potential candidates for detection by less sensitive techniques than 
multiplex assay, and development into tests for routine clinical use. 
Furthermore, their higher levels in plasma imply that these biomarkers 
would be detectable in the dried blood spots as shown by previous 
studies on IP-10 on dry blood spots [26,27]. This opens the possibility of 
developing a point-of-care test based on these biomarkers. Dried blood 
spots are easy to make and can be transported at ambient temperature to 
a reference laboratory. 
After 2 months of treatment, patients that responded well to treat-
ment showed marked change in biomarkers levels as compared to the 
partial responders, indicating that significant change in plasma levels of 
inflammatory biomarkers correlates with good clinical response and can 
be used to predict response to treatment during initial months of the 
therapy. Since majority of the partial responders at 2 months required 
prolongation of treatment, these biomarkers can also be used to predict 
the need for prolonged duration of treatment to achieve satisfactory 
response. Previous studies have shown that inflammatory markers can 
be used for the evaluation of the early treatment response [20,28]. 
All patients in our cohort showed good response to treatment at the 
end of treatment. This is not in agreement with our clinical experience 
and experience from other cohorts [29]. Usually, some of the patients 
started on anti-TB treatment on clinical suspicion do not show satis-
factory response to treatment. This could be due to the bias introduced 
by the study design, as the attending physician knew about the ongoing 
study and was extra careful in the selection of patients before the start of 
anti-TB treatment. Whereas in routine practice more liberal prescription 
of anti-TB treatment is done in presumptive EPTB cases due to lack of a 
reliable diagnostic test, leading to overdiagnosis and overtreatment. 
Diabetes mellitus has been documented as a risk factor for TB 
[30,31], and the prevalence of diabetes in Pakistan is reported to be 
around 26% [32]. However, only 4 patients (5%) in our cohort were 
diabetics. This is in agreement with our previous studies on EPTB where 
the prevalence of diabetes has been shown to be low among EPTB pa-
tients in Zanzibar (2%) [33], and India (2%) [34]. We also reported low 
prevalence of diabetes among pulmonary TB patients from Pakistan 
(5%) [35]. In agreement, another study from India has also reported low 
prevalence (5.4%) of diabetes among 37 EPTB patients [36], implying 
that diabetes might not be a risk factor for EPTB. However, this study 
was not designed to study the correlation between diabetes and EPTB, 
Fig. 6. Ratio/pirate plots to visualize the 
decrease or increase in plasma levels of in-
flammatory biomarkers in the individual 
tuberculous pleuritis patients. Only those 
inflammatory biomarkers that changed 
significantly with treatment are shown. a: 
Ratio of plasma level of inflammatory bio-
markers at 2 months of treatment to their 
levels at the start of treatment (n = 26). 
*Outliers: CCL13: 11 & 13, CCL26: 6; 9; 9; 
16; 21; 28; 29& 37, CXCL2: 11, IL8: 7; 8; 11; 
12; 25; 30; 43; 44 & 77. IL4: 130. b: Ratio of 
plasma levels of inflammatory biomarkers at 
6 months of treatment to their levels at the 
start of treatment (n = 35). *Outliers: CCL19: 
14, CCL2: 6, CCL20: 12 & 19, CCL23: 7, 
CCL3: 10 & 36, IL4: 36, IL6: 47, MIF: 15; 16; 
19 & 21.   
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and further studies are needed to address this. 
Our study has few weaknesses, i) all patients included in the study 
did not have bacteriologically confirmed TB. However, this reflects the 
situation in routine clinical practice due to the paucibacillary nature of 
the EPTB, making our results more generalized for a heterogeneous 
group of patients. ii) Relapse rate was not studied as patients were not 
followed-up after completion of treatment. iii) Our sample size was not 
as large as we had anticipated, as many EPTB patients registered for anti- 
TB treatment refused to give blood samples for research purposes or 
were lost to follow-up. The results from this study need to be validated in 
larger patient populations as well as in different epidemiological 
settings. 
Fig. 7. Venn diagram showing common inflam-
matory biomarkers that changed significantly at 
different time points in tuberculous (TB) lymph-
adenitis and pleuritis patients, n: number of pa-
tients, 0 M–2 M: Significant change at 2 months 
of the treatment as compared to baseline, 0 M–6 
M: Significant change at 6 months of the treat-
ment as compared to baseline, ↑: significant in-
crease in plasma levels with treatment, ↓: 
significant decrease in plasma levels with treat-
ment, *CCL3 levels increased significantly at 2 M 
in lymphadenitis patients, whereas it decreased 
significantly in pleuritis patients.   
Table 4 
The proportion of EPTB patients showing significant change in the levels of five biomarkers constituting the biosignatures at 2 and 6 months of treatment, and the 
sensitivity of the biosignatures to predict response to treatment.  
Immune Biomarkers 
(Median at 0–2-6 months pg/ml) 
All samples 
(0 M–2 M) 
N = 64 
n (%) 
All samples 
(0 M− 6 M) 
N = 75 
n (%) 
Responders 
(0 M− 2 M) 
N = 35 
n (%) 
Partial responders 
(0 M− 2 M) 




(2276 – 1418 – 568) 
43 (67) 60 (80) 28(80) 15 (52) .016 
IP-10 
(481 – 269 – 233) 
41 (64) 49 (65) 26 (74) 15 (52) .061 
MIF 
(13990 – 9407 – 5773) 
36 (56) 52 (69) 21 (60) 15 (52) .506  
CCL22 
(884 – 626 – 670) 
42 (66) 32 (43) 25 (71) 17 (59) .283 
CCL23 
(468 – 327 – 301) 
33 (52) 47/74* (64) 18 (51) 15 (52) .910 
MIG + IP-10 51 (80) 66 (88) 32 (91) 19 (66) .010 
MIG + CCL23 51 (80) 70 (93) 31 (89) 20 (69) .052 
MIG + MIF 54 (84) 68 (91) 31 (89) 23 (79) .310 
MIG + CCL22 54 (84) 64 (85) 33 (94) 21 (72) .016 
MIG + IP-10 + CCL22 57 (89) 67 (89) 34 (97) 23 (79) .023 
MIG + MIF + CCL23 59 (92) 74 (99) 33 (94) 26 (90) .492 
MIG + MIF + IP-10 58 (91) 72 (96) 34 (97) 24 (83) .049 
MIG + IP-10 + CCL23 54 (84) 70 (93) 32 (91) 22 (76) .088 
IP-10 + MIF + CCL23 59 (92) 70 (93) 33 (94) 26 (90) .492 
MIG + IP-10 + MIF + CCL22 61 (95) 72 (96) 35 (100) 26 (90) .051 
MIG + MIF + IP-10 + CCL23 60 (94) 74 (99) 34 (97) 26 (90) .218 
MIG + MIF + IP-10 + CCL22 + CCL23 62 (97) 74 (99) 35 (100) 27 (93) .114 
n: number of patients showing significant change, N: total number of patients, M: month of treatment. 
* Valid available values. 
** Chi-square test was done to see difference of biomarkers coverage among responders and partial responders at 2 months of treatment. A p-value < 0.05 was 
considered statistically significant 
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5. Conclusion 
A biosignature including MIG, IP-10, MIF, CCL22, and CCL23 was 
reliable in predicting response to treatment in EPTB at 2 and 6 months 
after standard anti-TB treatment in our study cohort. Relatively high 
plasma levels of biomarkers included in the biosignature imply the 
possibility of developing it further into a test for routine use by using less 
sensitive ELISA method and using less invasive sampling as dry blood 
spots. 
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